JP2016501066A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501066A5
JP2016501066A5 JP2015542401A JP2015542401A JP2016501066A5 JP 2016501066 A5 JP2016501066 A5 JP 2016501066A5 JP 2015542401 A JP2015542401 A JP 2015542401A JP 2015542401 A JP2015542401 A JP 2015542401A JP 2016501066 A5 JP2016501066 A5 JP 2016501066A5
Authority
JP
Japan
Prior art keywords
solution
composition
blood vessel
subject
effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015542401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501066A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/060145 external-priority patent/WO2014076660A1/en
Publication of JP2016501066A publication Critical patent/JP2016501066A/ja
Publication of JP2016501066A5 publication Critical patent/JP2016501066A5/ja
Pending legal-status Critical Current

Links

JP2015542401A 2012-11-14 2013-11-14 血管塞栓システム Pending JP2016501066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726250P 2012-11-14 2012-11-14
US61/726,250 2012-11-14
PCT/IB2013/060145 WO2014076660A1 (en) 2012-11-14 2013-11-14 Vascular embolic system

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018032093A Division JP2018086425A (ja) 2012-11-14 2018-02-26 血管塞栓システム
JP2019091205A Division JP2019122875A (ja) 2012-11-14 2019-05-14 血管塞栓システム

Publications (2)

Publication Number Publication Date
JP2016501066A JP2016501066A (ja) 2016-01-18
JP2016501066A5 true JP2016501066A5 (enExample) 2019-02-14

Family

ID=49725176

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015542401A Pending JP2016501066A (ja) 2012-11-14 2013-11-14 血管塞栓システム
JP2018032093A Pending JP2018086425A (ja) 2012-11-14 2018-02-26 血管塞栓システム
JP2019091205A Pending JP2019122875A (ja) 2012-11-14 2019-05-14 血管塞栓システム
JP2021114234A Withdrawn JP2021164739A (ja) 2012-11-14 2021-07-09 血管塞栓システム
JP2023103314A Pending JP2023115128A (ja) 2012-11-14 2023-06-23 血管塞栓システム
JP2024231414A Pending JP2025031996A (ja) 2012-11-14 2024-12-26 血管塞栓システム

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018032093A Pending JP2018086425A (ja) 2012-11-14 2018-02-26 血管塞栓システム
JP2019091205A Pending JP2019122875A (ja) 2012-11-14 2019-05-14 血管塞栓システム
JP2021114234A Withdrawn JP2021164739A (ja) 2012-11-14 2021-07-09 血管塞栓システム
JP2023103314A Pending JP2023115128A (ja) 2012-11-14 2023-06-23 血管塞栓システム
JP2024231414A Pending JP2025031996A (ja) 2012-11-14 2024-12-26 血管塞栓システム

Country Status (5)

Country Link
US (3) US20160287744A1 (enExample)
EP (1) EP2919826B1 (enExample)
JP (6) JP2016501066A (enExample)
HK (1) HK1215200A1 (enExample)
WO (1) WO2014076660A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102170919A (zh) 2008-10-06 2011-08-31 三维肽胶株式会社 组织闭塞剂
EP3466964A1 (en) 2012-07-06 2019-04-10 3-D Matrix Ltd. Fill-finish process for peptide solutions
WO2014076660A1 (en) * 2012-11-14 2014-05-22 3-D Matrix Ltd. Vascular embolic system
CN117138022A (zh) 2014-03-10 2023-12-01 三维矩阵有限责任公司 自组装肽组合物
EP3628337B1 (en) 2014-03-10 2025-05-28 3-D Matrix, Ltd. Sterilization and filtration of peptide compositions
ES2712608T3 (es) 2014-03-10 2019-05-14 3 D Matrix Ltd Péptidos autoensamblantes para el tratamiento de las bullas pulmonares
EP3221859B1 (en) * 2014-11-18 2020-10-21 Maximum Fidelity Surgical Simulations, LLC Post mortem reconstitution of circulation
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
AU2017232550A1 (en) * 2016-03-18 2018-09-27 3-D Matrix, Ltd. Cerebrospinal fluid leakage occlusion
CN109152868A (zh) * 2016-03-18 2019-01-04 立美基股份有限公司 防止生物组织粘连
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
PE20200719A1 (es) 2017-11-13 2020-07-21 Maximum Fidelity Surgical Simulations Llc Reconstitucion de la circulacion posmortem, metodos y procedimientos especializados
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
IL304283B2 (en) 2020-03-31 2024-12-01 3 D Matrix Ltd Sterilization of self-assembling peptides by irradiation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10127754A (ja) * 1996-11-06 1998-05-19 Koken Co Ltd コラーゲンからなる塞栓材
EP4023240A1 (en) * 2004-07-06 2022-07-06 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof
US7790699B2 (en) * 2004-10-12 2010-09-07 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
US9987221B2 (en) * 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
CN102170919A (zh) * 2008-10-06 2011-08-31 三维肽胶株式会社 组织闭塞剂
JP2012100680A (ja) * 2009-03-04 2012-05-31 Terumo Corp 血管内用処置材
WO2011014722A2 (en) * 2009-07-30 2011-02-03 Cook Incorporated Erodible embolization material
US20110117195A1 (en) * 2009-11-18 2011-05-19 National Cheng Kung University Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers
CA2831414C (en) * 2011-03-30 2016-03-22 Toray Industries, Inc. Biodegradable particle, vascular embolization material and method for producing biodegradable particles
WO2014076660A1 (en) * 2012-11-14 2014-05-22 3-D Matrix Ltd. Vascular embolic system

Similar Documents

Publication Publication Date Title
JP2016501066A5 (enExample)
Gonzalez et al. Animal models of ischemia-reperfusion-induced intestinal injury: progress and promise for translational research
Lam et al. Advanced progress of microencapsulation technologies: In vivo and in vitro models for studying oral and transdermal drug deliveries
Deng et al. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib
Liu et al. Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts
Yang et al. mTOR-mediated immunometabolic reprogramming nanomodulators enable sensitive switching of energy deprivation-induced microglial polarization for Alzheimer’s disease management
Chugh et al. Cerebral vasospasm and delayed cerebral ischemia: Review of literature and the management approach
JP2014513722A5 (enExample)
JP2016513523A5 (enExample)
ES2657901T3 (es) Utilidad ampliada de las micropartículas derivadas de glóbulos rojos (RMP) para el tratamiento de la hemorragia
Soliman et al. Miktoarm star micelles containing curcumin reduce cell viability of sensitized glioblastoma
US10220019B2 (en) Method for treating pulmonary fibrosis comprising application of dimethylamino micheliolide
CN105520934A (zh) 含笑内酯二甲基胺的应用
Makedonova et al. Studying clinical and pathomorphological changes in gingival tissues when applying platelet-rich autoplasma regenerative method
Li et al. Challenges of mesenchymal stem cells in the clinical treatment of COVID-19
CN107921075A (zh) 用于治疗肿瘤的细小病毒制剂
CN110279673A (zh) AuNP@PP/poly(I:C)及其制备方法与其在制备治疗胶质瘤药物中的应用
AU2020208472A1 (en) Fibroblasts and microvesicles thereof for reduction of toxicity associated with cancer immunotherapy
TWI531364B (zh) γ－紅沒藥烯（γ－Ｂｉｓａｂｏｌｅｎｅ）於治療口腔癌之用途
CN105287467A (zh) 胍丁胺在制备治疗脓毒症血管内皮损伤药物中的用途
CN120617283A (zh) 基于dna损伤激活nkt细胞的抗白血病药物组合物及其应用
Hayashi Effects of TNFR1 Inhibition on Neuropathological Outcomes in a Controlled Cortical Impact Mouse Model of Traumatic Brain Injury
Ali et al. Covid-19: a novel challenge to human immune genetic machinery
He et al. Anatomical and clinical study of lingual arterial chemoembolization for tongue carcinoma
Yenari Neel S. Singhal, Raymond A. Swanson, and Midori A. Yenari